Viekira Pak Dosage
Generic name: OMBITASVIR HEMINONAHYDRATE 12.5mg, PARITAPREVIR DIHYDRATE 75mg, RITONAVIR 50mg; DASABUVIR SODIUM MONOHYDRATE 250mg
Dosage form: tablets
Drug class: Antiviral combinations
Medically reviewed by Drugs.com. Last updated on Nov 21, 2022.
2.1 Testing Prior to the Initiation of Therapy
- Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with VIEKIRA PAK [see Warnings and Precautions (5.1)].
- Prior to initiation of VIEKIRA PAK, assess for laboratory and clinical evidence of hepatic decompensation [see Warnings and Precautions (5.2 and 5.3)].
2.2 Recommended Dosage in Adults
VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets.
The recommended oral dosage of VIEKIRA PAK is two ombitasvir, paritaprevir, ritonavir tablets once daily (in the morning) and one dasabuvir tablet twice daily (morning and evening). Take VIEKIRA PAK with a meal without regard to fat or calorie content [see Clinical Pharmacology (12.3)].
VIEKIRA PAK is used in combination with ribavirin (RBV) in certain patient populations (see Table 1). When administered with VIEKIRA PAK, the recommended dosage of RBV is based on weight: 1000 mg/day for subjects <75 kg and 1200 mg/day for those ≥75 kg, divided and administered twice-daily with food. For ribavirin dosage modifications, refer to the ribavirin prescribing information.
For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. Refer to Drug Interactions (7) for dosage recommendations for concomitant HIV-1 antiviral drugs.
Table 1 shows the recommended VIEKIRA PAK treatment regimen and duration based on patient population.
|VIEKIRA PAK + ribavirin||12 weeks|
with compensated cirrhosis
|VIEKIRA PAK + ribavirin||24 weeks**|
with or without compensated
cirrhosis (Child-Pugh A)
|VIEKIRA PAK||12 weeks|
|*Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.
**VIEKIRA PAK administered with ribavirin for 12 weeks may be considered for some patients based on prior treatment history [see Clinical Studies (14.3)].
2.3 Use in Liver Transplant Recipients
In liver transplant recipients with normal hepatic function and mild fibrosis (Metavir fibrosis score 2 or lower), the recommended duration of VIEKIRA PAK with ribavirin is 24 weeks, irrespective of HCV genotype 1 subtype [see Clinical Studies (14.6)]. When VIEKIRA PAK is administered with calcineurin inhibitors in liver transplant recipients, dosage adjustment of calcineurin inhibitors is needed [see Drug Interactions (7)].
Frequently asked questions
- What's the difference between Viekira Pak and Viekira XR?
- What are the new drugs for the treatment of hepatitis C?
More about Viekira Pak (dasabuvir / ombitasvir / paritaprevir / ritonavir)
- Check interactions
- Pricing & coupons
- Reviews (13)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.